FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Asset / Drug

tagitanlimab

Drug and asset intelligence for tagitanlimab with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 1
Stage: Development stage unavailable

Mechanism of action

Combination Therapy

Recent signals(1)

ClinicalJuly 15, 2026

Phase II Trial of Sacituzumab Tirumotecan and Tagitanlimab in Advanced Esophageal and Gastric Cancers

A phase II trial is underway to assess the efficacy and safety of sacituzumab tirumotecan combined with tagitanlimab in patients with recurrent or metastatic esophageal squamous cell carcinoma and gastric adenocarcinoma.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

— tagitanlimab

July 15, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Combination Therapy →

Oncology →

Oncology · Combination Therapy →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.